Dr. Michael L. Haas
Claim this profileReading Hospital
Studies Cancer
Studies Squamous Cell Carcinoma
11 reported clinical trials
43 drugs studied
Area of expertise
1Cancer
Stage IV
p16 negative
Stage I
2Squamous Cell Carcinoma
p16 negative
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Michael L. Haas is currently running
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
More about Michael L. Haas
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Michael L. Haas has experience with
- Intensity-Modulated Radiation Therapy
- Atezolizumab
- Cisplatin
- Stereotactic Body Radiation Therapy
- Nivolumab
- Image Guided Radiation Therapy
Breakdown of trials Michael L. Haas has run
Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael L. Haas specialize in?
Michael L. Haas focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are p16 negative.
Is Michael L. Haas currently recruiting for clinical trials?
Yes, Michael L. Haas is currently recruiting for 9 clinical trials in West Reading Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Michael L. Haas has studied deeply?
Yes, Michael L. Haas has studied treatments such as Intensity-Modulated Radiation Therapy, Atezolizumab, Cisplatin.
What is the best way to schedule an appointment with Michael L. Haas?
Apply for one of the trials that Michael L. Haas is conducting.
What is the office address of Michael L. Haas?
The office of Michael L. Haas is located at: Reading Hospital, West Reading, Pennsylvania 19611 United States. This is the address for their practice at the Reading Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.